Israel - English - Ministry of Health

eisai israel ltd., israel - lenvatinib as mesilate - hard capsule - lenvatinib as mesilate 10 mg - lenvatinib - lenvima is indicated for the treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/hürthle cell) thyroid carcinoma (dtc), refractory to radioactive iodine (rai).lenvima is indicated in combination with everolimus for the treatment of adult patients with advanced clear cell renal cell carcinoma (rcc) following one prior vascular endothelial growth factor (vegf)-targeted therapy.lenvima is indicated as monotherapy for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (hcc) who have received no prior systemic therapy.lenvima, in combination with pembrolizumab, is indicated for the treatment of adult patients with advanced or recurrent endometrial carcinoma who have disease progression on or following prior treatment with a platinum containing therapy and who are not candidates for curative surgery or radiation.lenvima is indicated in combination with pembrolizumab for the first-line treatment of adult patients with advanced rcc.

Israel - English - Ministry of Health

eisai israel ltd., israel - lenvatinib as mesilate - hard capsule - lenvatinib as mesilate 4 mg - lenvatinib - lenvima is indicated for the treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/hürthle cell) thyroid carcinoma (dtc), refractory to radioactive iodine (rai).lenvima is indicated in combination with everolimus for the treatment of adult patients with advanced clear cell renal cell carcinoma (rcc) following one prior vascular endothelial growth factor (vegf)-targeted therapy.lenvima is indicated as monotherapy for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (hcc) who have received no prior systemic therapy.lenvima, in combination with pembrolizumab, is indicated for the treatment of adult patients with advanced or recurrent endometrial carcinoma who have disease progression on or following prior treatment with a platinum containing therapy and who are not candidates for curative surgery or radiation.lenvima is indicated in combination with pembrolizumab for the first-line treatment of adult patients with advanced rcc.

Israel - English - Ministry of Health

padagis israel agencies ltd, israel - digoxin - elixir - digoxin 0.05 mg / 1 ml - digoxin - digoxin - lanoxin is indicated whenever digitalis therapy is required for the treatment of congestive heart failure, atrial fibrilation and/or flutter and supra-ventricular tachycardia.

Israel - English - Ministry of Health

merck serono ltd - bisoprolol fumarate - tablets - bisoprolol fumarate 10 mg - bisoprolol - bisoprolol - - treatment of stable chronic, moderate to severe heart failure with impaired systolic ventricular function ( ejection fraction < 35 %, determined by echocardiography) in addition to ace inhibitors and diuretics, and optionally cardiac glycosides.- hypertension- coronary heart disease (angina pectoris)

Israel - English - Ministry of Health

teva pharmaceutical industries ltd, israel - verapamil hydrochloride - tablets - verapamil hydrochloride 40 mg - verapamil - verapamil - angina pectoris, cardiac arrhythmias, hypertension.

Israel - English - Ministry of Health

teva pharmaceutical industries ltd, israel - verapamil hydrochloride - tablets - verapamil hydrochloride 120 mg - verapamil - verapamil - angina pectoris, cardiac arrhythmias, hypertension.

Israel - English - Ministry of Health

teva pharmaceutical industries ltd, israel - verapamil hydrochloride - tablets slow release - verapamil hydrochloride 240 mg - verapamil - verapamil - mild to moderate hypertension. angina pectoris.

Israel - English - Ministry of Health

teva pharmaceutical industries ltd, israel - verapamil hydrochloride - tablets sustained release - verapamil hydrochloride 180 mg - verapamil - verapamil - mild to moderate hypertention. angina pectoris.

Israel - English - Ministry of Health

j-c health care ltd - haloperidol - tablets - haloperidol 5 mg - haloperidol - haloperidol - haldol is indicatedin adult patients aged 18 years and above for:• treatment of schizophrenia and schizoaffective disorder.• acute treatment of delirium when non-pharmacological treatments have failed.• treatment of moderate to severe manic episodes associated with bipolar i disorder when other treatments cannot be used.• treatment of acute psychomotor agitation associated with psychotic disorder or manic episodes of bipolar i disorder.• treatment of persistent aggression and psychotic symptoms in patients with moderate to severe alzheimer’s dementia and vascular dementia when non-pharmacological treatments have failed and when there is a risk of harm to self or others.• treatment of tic disorders, including tourette’s syndrome, in patients with severe impairment after educational, psychological and other pharmacological treatments have failed.• treatment of mild to moderate chorea in huntington’s disease, when other medicinal products are ineffective or not tolerated.in paediatric patients for:• schizophrenia in adolescents aged 13 to 17 years when other pharmacological treatments have failed or are not tolerated.• persistent, severe aggression in children and adolescents aged 6 to 17 years with autism or pervasive developmental disorders, when other treatments have failed or are not tolerated. • tic disorders, including tourette’s syndrome, in children and adolescents aged 10 to 17 years with severe impairment after educational, psychological and other pharmacological treatments have failed.

Israel - English - Ministry of Health

j-c health care ltd - haloperidol - solution (oral) - haloperidol 2 mg/ml - haloperidol - haloperidol - haldol is indicatedin adult patients aged 18 years and above for:• treatment of schizophrenia and schizoaffective disorder.• acute treatment of delirium when non-pharmacological treatments have failed.• treatment of moderate to severe manic episodes associated with bipolar i disorder when other treatments cannot be used.• treatment of acute psychomotor agitation associated with psychotic disorder or manic episodes of bipolar i disorder.• treatment of persistent aggression and psychotic symptoms in patients with moderate to severe alzheimer’s dementia and vascular dementia when non-pharmacological treatments have failed and when there is a risk of harm to self or others.• treatment of tic disorders, including tourette’s syndrome, in patients with severe impairment after educational, psychological and other pharmacological treatments have failed.• treatment of mild to moderate chorea in huntington’s disease, when other medicinal products are ineffective or not tolerated.in paediatric patients for:• schizophrenia in adolescents aged 13 to 17 years when other pharmacological treatments have failed or are not tolerated.• persistent, severe aggression in children and adolescents aged 6 to 17 years with autism or pervasive developmental disorders, when other treatments have failed or are not tolerated. • tic disorders, including tourette’s syndrome, in children and adolescents aged 10 to 17 years with severe impairment after educational, psychological and other pharmacological treatments have failed.